The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
The price increases are due to the rising costs of raw materials.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
Building upon the momentum gained by pharma sector during the pandemic, Indian Pharmaceutical Alliance is leaving no stone unturned to create a faster road to recovery.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated
